Myokarditis und entzündliche Kardiomyopathie

Carsten Tschöpe; Uwe Kühl

doi:10.1055/s-0041-107710

DMW - Deutsche Medizinische Wochenschrift, Table of Contents

Dtsch Med Wochenschr 2016; 141(2): 95-102
DOI: 10.1055/s-0041-107710

Dossier

Myokarditis / Kardiomyopathie

Myokarditis und entzündliche Kardiomyopathie

Aktuelle BehandlungsmöglichkeitenMyocarditis and inflammatory cardiomyopathy – current treatment options

Authors

Carsten Tschöpe

¹Medizinische Klinik mit Schwerpunkt Kardiologie, Charité – Universitätsmedizin Berlin, Campus Virchow Klinikum (CVK), Augustenburgerplatz 1, D-13353 Berlin

²Berliner Centrum für Regenerative Therapien (BCRT)
Uwe Kühl

¹Medizinische Klinik mit Schwerpunkt Kardiologie, Charité – Universitätsmedizin Berlin, Campus Virchow Klinikum (CVK), Augustenburgerplatz 1, D-13353 Berlin

Abstract

Zusammenfassung

Die Behandlung einer Herzinsuffizienz oder von Rhythmusstörungen im Rahmen einer akuten oder chronischen Myokarditis erfolgt, unabhängig von der auslösenden Ursache, symptomatisch nach allgemeinen Evidenz-basierten Leitlinien. Akute stabile Myokarditiden benötigen meist zunächst keinen spezifischen Therapieansatz. Akut sich rasch verschlechternde Patienten müssen jedoch schnell myokardbioptisch differenzialdiagnostisch analysiert werden, um ggf. immunsuppressive Therapieansätze z. B. bei der Riesenzellmyokarditis, eosinophilen oder granulomatösen Myokarditiden sofort initiieren zu können. Bei chronischen Verläufen ist nach myokardbioptischem Ausschluss einer Viruspersistenz eine Immunsuppression sinnvoll. Bei Nachweis einer Viruspersistenz (Adeno/Enteroviren) stellt Interferon-Beta die Therapieoption dar. Symptomatische Patienten mit Nachweis vaskulotroper Erythro- und/oder Herpesviren können von den oben beschriebenen Therapieversuchen unter Umständen profitieren [16], [46].

Abstract

Myocarditis is a cardiac inflammatory disease mainly caused by autoimmune processes and/or viral infections. Despite the advances of non-invasive diagnostic tests, endomyocardial biopsies (EMBs) remains the gold standard diagnostic technique for myocarditis and inflammatory cardiomyopathy. If the immune response fails to eliminate the infectious agent or inflammatory process does not resolve, only EMB can elucidate the cause and the status of the disease. Such tissue analyses are the prerequisite for an initiation of a specific antiviral or an anti-inflammatory treatment in addition to basic heart failure therapy. Other conditions such as giant cell myocarditis or cardiac sarcoidosis benefit from an anti-inflammatory treatment during the acute phase, so EMB has an important role both in acute and chronic settings. Despite the promising results with immunosuppressive or antiviral therapy in specific clinical scenarios according to published data, larger randomized studies are warranted in order to detect the effect of these treatments in strong clinical endpoints.

Schlüsselwörter

Myokarditis - Virusinfektion - Behandlung - Herzversagen

Keywords

myocarditis - viral infection - treatment - heart failure

Full Text

References

Literatur
1 Grün S, Schumm J, Greulich S et al. Long-term follow-up of biopsy-proven viral myocarditis. Predictors of mortality and incomplete recovery. J Am Coll Cardiol 2012; 59: 1604-1615
2 Kuhl U, Pauschinger M, Noutsias M et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with “idiopathic” left ventricular dysfunction. Circulation 2005; 111: 887-893
3 Baboonian C, Treasure T. Meta-analysis of the association of enteroviruses with human heart disease. Heart 1997; 78: 539-543
4 D’Ambrosio A, Patti G, Manzoli A et al. The fate of acute myocarditis between spontaneous improvement and evolution to dilated cardiomyopathy: a review. Heart 2001; 85: 499-504
5 Friedrich MG, Sechtem U, Schulz-Menger J et al. Cardiovascular magnetic resonance in myocarditis: A JACC White Paper. J Am Coll Cardiol 2009; 53: 1475-1487
6 Gutberlet M, Spors B, Thoma T et al. Suspected chronic myocarditis at cardiac MR: diagnostic accuracy and association with immunohistologically detected inflammation and viral persistence. Radiology 2008; 246: 401-409
7 Lurz P, Eitel I, Adam J et al. Diagnostic Performance of CMR Imaging Compared With EMB in Patients With Suspected Myocarditis. J Am Coll Cardiol Img 2012; 5: 513-524
8 Aretz HT. Myocarditis: the Dallas criteria. Hum Pathol 1987; 18: 619-624
9 Escher F, Kühl U, Lassner D et al. Presence of perforin in endomyocardial biopsies of patients with inflammatory cardiomyopathy predicts poor outcome. Eur J Heart Fail 2014; 16: 1066-1072
10 Kuhl U, Noutsias M, Seeberg B, Schultheiss HP. Immunohistological evidence for a chronic intramyocardial inflammatory process in dilated cardiomyopathy. Heart 1996; 75: 295-300
11 Noutsias M, Seeberg B, Schultheiss HP, Kuhl U. Expression of cell adhesion molecules in dilated cardiomyopathy: evidence for endothelial activation in inflammatory cardiomyopathy. Circulation 1999; 99: 2124-2131
12 Schultheiss HP, Kuehl U, Cooper LT. The management of myocarditis. Eur Heart J 2011; 32: 2616-2665
13 Liu PP, Schultheiss HP. Myocarditis. In: Libby P, Bonow RO, Zipes DP, Mann DL. Baunwald’s Heart Disease. 8. Aufl. Philadelphia: Saunders; 2008
14 Caforio AL, Calabrese F, Angelini A et al. A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis. Eur Heart J 2007; 28: 1326-1333
15 Kühl U, Lassner D, von Schlippenbach J et al. Interferon-beta improves survival in enterovirus-associated cardiomyopathy. J Am Coll Cardiol 2012; 60: 1295-1296
16 Kühl U, Lassner D, Wallaschek N et al. Chromosomally integrated human herpesvirus 6 in heart failure – prevalence and treatment. Eur J Heart Fail 2015; 17: 9-19
17 Kühl U, Pauschinger M, Schwimmbeck PL et al. Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation 2003; 107: 2793-2798
18 Kühl U, Pauschinger M, Noutsias M et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with “idiopathic” left ventricular dysfunction. Circulation 2005; 111: 887-893
19 Magnani JW, Suk Danik HJ, Dec GW, DiSalvo TG. Survival in biopsy-proven myocarditis: A long-term retrospective analysis of the histopathological, clinical, and hemodynamic predictors. Am Heart J 2006; 151: 463-470
20 Tschope C, Kherad B, Schultheiss HP. How to perform an endomyocardial biopsy? Turk Kardiyol Dem Ars. 2015; 43: 572-575
21 Hunt SA, Abraham WT, Chin MH et al. 2009 focused update incorporated into the ACC / AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation / American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119: e391-479
22 McCarthy 3 rd RE, Boehmer JP, Hruban RH et al. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med 2000; 342: 690-695
23 Cooper L, Hare JM, Tazelaar HD et al. Usefulness of Immunosuppression for Giant Cell Myocarditis. Am J Cardiol 2008; 102: 1535-1539
24 Lassner D, Kuehl U, Siegesmund CS et al. Improved diagnosis of idiopathic giant cell myocarditis and cardiac sarcoidosis by myocardial gene expression profiling. Europ Heart J 2014; 35: 2186-2195
25 Mason JW, O’Connell JB, Herskowitz A et al. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med 1995; 333: 269-275
26 Parrillo JE, Cunnion RE, Epstein SE et al. A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy. N Engl J Med 1989; 321: 1061-1068
27 Frustaci A, Chimenti C, Calabrese F et al. Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders versus nonresponders. Circulation 2003; 107: 857-863
28 Schultheiss HP, Kuhl U. Myocarditis. Dtsch Med Wochenschr 2008; 133: Suppl-S290–294
29 Wojnicz R, Nowalany-Kozielska E, Wojciechowska C et al. Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy: two-year follow-up results. Circulation 2001; 104: 39-45
30 Kuehl U, Lassner D, Wallaschek N et al. Chromosomally integrated human herpesvirus 6 in heart failure – prevalence and treatment. Eur J Heart Fail 2015; 17: 9-19
31 Maleszewski JJ, Orellana VM, Hodge DO et al. Long-term risk of recurrence, morbidity and mortality in giant cell myocarditis. Am J Cardiol 2015; 115: 1733-1738
32 Frustaci A, Russo MA, Chimenti C. Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study. Eur Heart J 2009; 30: 1995-2002
33 Caforio AL, Pankuweit S, Arbustini E et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 2013; 34: 2636-2648
34 Stanton C, Mookadam F, Cha S et al. Greater symptom duration predicts response to immunomodulatory therapy in dilated cardiomyopathy. Int J Cardiol 2008; 128: 38-41
35 McNamara DM, Holubkov R, Starling RC et al. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation 2001; 103: 2254-2259
36 Felix SB, Staudt A. Non-specific immunoadsorption in patients with dilated cardiomyopathy: mechanisms and clinical effects. Int J Cardiol 2006; 112: 30-33
37 Felix SB, Staudt A, Friedrich GB. Improvement of cardiac function after immunoadsorption in patients with dilated cardiomyopathy. Autoimmunity 2001; 34: 211-215
38 Ameling S, Herda LR, Hammer E et al. Myocardial gene expression profiles and cardiodepressant autoantibodies predict response of patients with dilated cardiomyopathy to immunoadsorption therapy. Europ Heart J 2013; 34: 666-675
39 Kuehl U, Schultheiss HP. Viral myocarditis. Swiss Med Wkly 2014; 144: W14010-0
40 Martino TA, Liu P, Sole MJ. Viral infection and the pathogenesis of dilated cardiomyopathy. Circ Res 1994; 74: 182-188
41 Wang YX, da Cunha V, Vincelette J et al. Antiviral and myocyte protective effects of murine interferon-beta and -{alpha}2 in coxsackievirus B3-induced myocarditis and epicarditis in Balb / c mice. Am J Physiol Heart Circ Physiol 2007; 293: H69-H76
42 Kühl U, Pauschinger M, Schwimmbeck PL et al. Interferon-beta treatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction. Circulation 2003; 107: 2793-2798
43 Kuehl U, Lassner D, Gast M et al. Differential cardiac microRNA expression predicts the clinical course in human enterovirus cardiomyopathy. Circ Heart Fail 2015; 8: 605-618
44 Schmidt-Lucke C, Zobel T, Schrepfer S et al. Impaired endothelial regeneration through human parvovirus B19-infected circulating angiogenic cells in cardiomyopathy. J Infect Dis 2015; 212: 1070-1081
45 Tschope C, Bock CT, Kasner M et al. High prevalence of cardiac parvovirus B19 infection in patients with isolated left ventricular diastolic dysfunction. Circulation 2005; 111: 879-886
46 Schmidt-Lucke C, Spillmann F, Bock T et al. Interferon-beta modulates endothelial damage in patients with cardiac persistance of parvovirus B19V. J Infectious Dis 2010; 201: 936-945
47 Pellett PE, Ablashi DV, Ambros PF et al. Chromosomally integrated human herpesvirus 6: questions and answers. Rev Med Virol 2012; 22: 144-155
48 Escher F, Kühl U, Gross U et al. Aggravation of left ventricular dysfunction in patients with biopsy-proven cardiac human herpesvirus A and B infection. J Clin Virol 2015; 63: 1-5
49 Leong HN, Tuke PW, Tedder RS et al. The prevalence of chromosomally integrated human herpesvirus 6 genomes in the blood of UK blood donors. J Med Virol 2007; 79: 45-51
50 Ward KN, Thiruchelvam AD, Couto-Parada X. Unexpected occasional persistence of high levels of HHV-6 DNA in sera: detection of variants A and B. J Med Virol 2005; 79: 563-570
51 Endo A, Watanabe K, Ohye T et al. Molecular and virological evidence of viral activation from chromosomally integreted human herpesvirus 6A in a patient with x-linked severe combined immunodeficiency. Clin Infec Dis 2014; 59: 545-548
52 Gravel A, Hall CB, Flammand L. Sequence analysis of transplacentally acquired human herpesvirus 6 DNA is consistent with transmission of a chromosomally integrated reactivated virus. J Infect Dis 2013; 207: 1585-1589
53 Toscano G, Tartaro P, Fedrigo M et al. Rituximab in recurrent idiopathic giant cell myocarditis after heart transplantation: a potential therapeutic approach. Transpl Int 2014; 27: e38-e42
54 Zouggari Y, Ait-Oufella H, Bonnin P et al. B lymphocytes trigger monocyte mobilization and impair heart function after acute myocardial infarction. Nat Med 2013; 19: 1273-1280
55 Kamiyoshi Y, Takahashi M, Yokoseki O et al. Mycophenolate mofetil prevents the development of experimental autoimmune myocarditis. J Mol Cell Cardiol 2005; 39: 467-477
56 Kühl U, Lassner D, Dorner A et al. A distinct subgroup of cardiomyopathy patients characterized by transcriptionally active cardiotropic erythrovirus and altered cardiac gene expression. Basic Res Cardiology 2013; 108: 372-382